Riluzole

Evidence Level: L5

Predicted Indications: 8

Riluzole

Pharmacist Assessment Report

Riluzole: From Amyotrophic Lateral Sclerosis to Bilateral Parasagittal Parieto-occipital Polymicrogyria

One-Sentence Summary

Riluzole is an oral drug originally used to treat amyotrophic lateral sclerosis (ALS). The TxGNN model predicts it may be effective for bilateral parasagittal parieto-occipital polymicrogyria, but no clinical trials and no publications currently support this specific prediction. It is a computational signal only.

Quick Overview

Item	Content
Original Indication	Amyotrophic lateral sclerosis
Predicted New Indication	Bilateral parasagittal parieto-occipital polymicrogyria
TxGNN Prediction Score	0.9999
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, riluzole is an established treatment for ALS and is generally described in the literature as acting on glutamate neurotransmission. Mechanistically, it might be applicable to a neurodevelopmental cortical malformation through glutamate modulation.

That link is speculative. Polymicrogyria is a structural malformation of the cortex that arises during development, and nothing in the data compiled for this report shows that dampening glutamate signalling would change its course. The very high score (0.9999) reflects the model’s pattern matching and is not clinical evidence.

Other top-ranked predictions are closer to the original indication, such as lower motor neuron syndrome with late-adult onset, monomelic amyotrophy, Mills syndrome, and ALS subtypes. They have some biological overlap with motor neuron disease, but they also lack trials or publications specific to those conditions.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the predicted indication.

For context, 20 publications were retrieved for a different prediction, the ALS susceptibility label (rank 8). These are mostly reviews on ALS pathophysiology and glutamate excitotoxicity, and they do not address polymicrogyria. Examples:

PMID	Year	Type	Journal	Key Findings
9178165	1997	Review	Journal of neurology	Glutamate excitotoxicity as a major mechanism of motor neuron injury in ALS
21128691	2011	Review	CNS drugs	Riluzole is the only medication shown to modestly prolong survival in ALS
42161327	2026	Genetic association study	Brain	CYP2D6 variants studied for ALS risk and survival

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
184257	Rilutor 50mg Tablet (Sun Pharmaceutical Industries Ltd)	Strip of 10 tablets	Not stated in the available data

Safety Considerations

Conditions flagged as contraindication-related (from the knowledge graph, not label text): neutropenia, agranulocytosis, substance abuse/dependence, hyperbilirubinemia, hereditary hyperbilirubinemia, Gilbert syndrome, interstitial lung disease, drug-induced liver injury.
Liver safety: a 2020 modelling study reports that about 50% of ALS patients on oral riluzole 50 mg tablets have ALT above the upper limit of normal, about 8% above 3× ULN and about 2% above 5× ULN.
Drug Interactions: 44 interactions were identified. Moderate-level interactions include obeticholic acid, naltrexone, deferasirox, osilodrostat, anagrelide, asparaginase Escherichia coli, brentuximab vedotin, clofarabine, methotrexate, and epirubicin. Minor-level interactions include omeprazole, caffeine, theophylline, and aminophylline.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone. There are no clinical trials or publications for polymicrogyria, and a plausible mechanism has not been established. Riluzole is already marketed in India for ALS, but that does not support this new use.

To proceed, the following is needed:

Package insert warnings and contraindications for the Indian product, which are needed before any safety screening
Riluzole’s mechanism of action data
Preclinical or mechanistic evidence linking glutamate modulation to polymicrogyria
Reassessment of closer ALS-spectrum predictions (lower motor neuron syndrome, monomelic amyotrophy, ALS subtypes), which may be better candidates for subtype-stratified evidence
Hepatic and haematological monitoring plans, given the liver-related and neutropenia/agranulocytosis flags
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.